Effects of Converting Tacrolimus Formulation from Twice-Daily to Once-Daily in Liver Transplantation Recipients

Abstract EN

Typically, tacrolimus is administrated twice daily.

Prolonged-release tacrolimus is the once-daily formulation and may be more convenient for patients.

Experience with the administration of the once-daily formulation is still limited.

This study enrolled 210 liver transplant recipients who had stable liver function and converted tacrolimus from a twice-daily to once-daily formulation on a 1 mg to 1 mg basis.

Among 210 patients, seven patients (3.3%) were withdrawn from the once-daily formulation due to allergy and fatigue.

For the other patients, the trough concentration after converting to the once-daily formulation was lower than that of the twice-daily formulation.

Liver enzymes were mildly elevated in 3 months after formulation conversion and serum creatinine and uric acid were mildly decreased.

Seven patients (3.4%) had clinical suspicion of acute rejection after the formulation conversion and three of them were caused by nonadherence.

155 patients (76.4%) experienced a more convenient life with an increase of social activity.

Forty-seven patients (23.2%) experienced the convenience of once-daily formulation during overseas trips.

In conclusion, tacrolimus can be safely converted from the twice-daily to the once-daily formulation for most stable liver recipients.

Acute rejection may occur in a minority of patients during formulation conversion and should be carefully monitored.